Rxbiologics

RxBiologics is a private, services-focused biotech company that provides antibody discovery and engineering services using its proprietary Galaxy® phage display library platform. Its core mission is to deliver high-quality, fully human antibody leads with superior affinity, stability, and specificity in a streamlined 'right first time' process. As a subsidiary of the integrated drug discovery group RxCelerate, it offers clients comprehensive packages from early discovery through preclinical development. The company is pre-revenue, operating on a collaborative, client-funded service model.

Proprietary Galaxy® antibody phage display library platform designed to generate fully human, drug-like antibodies with high affinity, stability, and specificity in a single-pass, 'Right first time' process.

RxBiologics competes in the crowded antibody discovery services sector against large multinational CROs (e.g., Lonza, Abzena), specialized discovery platforms (e.g., Biolojic Design, Distributed Bio), and in-house capabilities at large pharma. Its differentiation hinges on the purported efficiency and quality advantages of its Galaxy® platform.